PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.

Phase 2

Terminated

Conditions: Pain

Interventions: Drug: [S,S]-Reboxetine
Drug: Any

First Posted Date: 2006-07-06

Last Posted Date: 2011-06-01

Lead Sponsor: Pfizer

Target Recruit Count: 136

Registration Number: NCT00348894

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Insulin Lispro
Drug: Exubera

First Posted Date: 2006-07-04

Last Posted Date: 2010-03-16

Lead Sponsor: Pfizer

Target Recruit Count: 191

Registration Number: NCT00348374

Locations: 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico

Morphine-Sparing Efficacy Of Parecoxib In Pain Treatment After Radical Prostatectomy

Phase 4

Terminated

Conditions: Pain, Postoperative

Interventions: Drug: Morphine, Parecoxib
Drug: Morphine, Placebo

First Posted Date: 2006-06-29

Last Posted Date: 2011-10-28

Lead Sponsor: Pfizer

Target Recruit Count: 105

Registration Number: NCT00346268

Locations: 🇩🇪
Pfizer Investigational Site, Reutlingen, Germany

Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer

Phase 2

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Sunitinib malate

First Posted Date: 2006-06-20

Last Posted Date: 2012-08-31

Lead Sponsor: Pfizer

Target Recruit Count: 120

Registration Number: NCT00338884

Locations: 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan

[S,S]-Reboxetine Add-On Trial

Phase 2

Terminated

Conditions: Pain

Interventions: Drug: [S,S]-Reboxetine + Pregabalin
Drug: Pregabalin

First Posted Date: 2006-06-08

Last Posted Date: 2019-12-16

Lead Sponsor: Pfizer

Target Recruit Count: 136

Registration Number: NCT00334685

Locations: 🇬🇧
Pfizer Investigational Site, York, United Kingdom

Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults

Phase 1

Completed

Conditions: Obesity

First Posted Date: 2006-05-29

Last Posted Date: 2006-12-15

Lead Sponsor: Pfizer

Target Recruit Count: 31

Registration Number: NCT00331175

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events

Phase 4

Completed

Conditions: Major Coronary Event
Cerebrovascular Accident
Coronary Artery Bypass Graft
Angina, Unstable
Revascularization

First Posted Date: 2006-05-18

Last Posted Date: 2007-05-10

Lead Sponsor: Pfizer

Target Recruit Count: 2800

Registration Number: NCT00327418

Locations: 🇬🇧
Pfizer Investigational Site, Wishaw, United Kingdom

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

Phase 4

Completed

Conditions: Cardiovascular Disease
Cerebrovascular Accident
Coronary Heart Disease

First Posted Date: 2006-05-18

Last Posted Date: 2007-05-03

Lead Sponsor: Pfizer

Target Recruit Count: 8600

Registration Number: NCT00327691

Locations: Pfizer Investigational Site

An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD

Phase 4

Terminated

Conditions: Age Related Macular Degeneration (AMD)
Macular Degeneration
Choroidal Neovascularization (CNV)

Interventions: Drug: Pegaptanib Sodium 0.3 mg

First Posted Date: 2006-05-18

Last Posted Date: 2012-04-04

Lead Sponsor: Pfizer

Target Recruit Count: 288

Registration Number: NCT00327470

Locations: 🇬🇧
Pfizer Investigational Site, Southampton, United Kingdom

Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

Phase 2

Completed

Conditions: Dyslipidemia

First Posted Date: 2006-05-16

Last Posted Date: 2009-05-07

Lead Sponsor: Pfizer

Target Recruit Count: 84

Registration Number: NCT00326326

Locations: 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy